Promaxo announced it raised $41.9 Million in an amended filing from an offering of $57.3 Million

Company

Location

About

With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient diagnosis and interventions. In March 2021, the company received 510(k) clearance from the U.S. FDA for its revolutionary office-based MRI system, allowing practices and hospitals to seamlessly guide prostate interventions under the single-sided scanner.